HCPCS Level II code J9015 denotes the single-use vial injection of aldesleukin, a recombinant interleukin-2 biologic used in certain oncology and immunotherapy settings. Nationally, this code matters because it captures administration of a high-cost injectable biologic that has implications for facility billing, payer coverage policies, and site-of-service cost differentials. Payers commonly applying coverage rules to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what J9015 represents, how it is used across typical sites of care (hospital outpatient departments, physician offices, and infusion centers), and which payers are relevant for coverage considerations. The publication provides benchmarks where available, summarizes common billing and coding themes tied to injectable biologics, and highlights recent policy trends affecting drug administration codes. It also outlines clinical context for aldesleukin administration and what information billing professionals and policy analysts should track when evaluating utilization and reimbursement for J9015. Data not provided in the input (such as associated taxonomies, ICD-10 diagnoses, and related codes) are noted as unavailable.